<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04949906</url>
  </required_header>
  <id_info>
    <org_study_id>M2019439</org_study_id>
    <nct_id>NCT04949906</nct_id>
  </id_info>
  <brief_title>Study on Yangxue Nao Granules Reducing the Risk of Stroke</brief_title>
  <official_title>A Real World Study of Yangxuenao Granules Reducing Bleeding Risk in Patients With Acute Ischemic Stroke Treated With Intravenous Thrombolysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University Third Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University Third Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective: To explore the effectiveness of raising serum nao granules in reducing the risk of&#xD;
      bleeding in patients with acute ischemic stroke treated with intravenous thrombolysis in the&#xD;
      real world&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective: To explore the effectiveness of raising serum nao granules in reducing the risk of&#xD;
      bleeding in patients with acute ischemic stroke treated with intravenous thrombolysis in the&#xD;
      real world Study Design. This study was a single center real world study. Through the review&#xD;
      data, this study included in January 1, 2017 to September 30, 2019, see a doctor at Peking&#xD;
      University third hospital neurology, emergency diagnosis of acute ischemic stroke, and venous&#xD;
      thrombolysis in patients with a queue, on the basis of whether the application have serum&#xD;
      brain particles are divided into a group and the control group, serum application parameters&#xD;
      and nonparametric comparison, K-M curve and Cox regression model were used to evaluate the&#xD;
      effectiveness of Yangxuenao granules in reducing bleeding conversion after intravenous&#xD;
      thrombolysis by comparing the number of microbleeding, stroke severity score and modified&#xD;
      Rankin score after 3 months follow-up with the weighted craniocerebral magnetic sensitivity&#xD;
      imaging sequence reexamined within 48 hours.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2019</start_date>
  <completion_date type="Actual">November 1, 2020</completion_date>
  <primary_completion_date type="Actual">September 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Microhemorrhage (CMB) of T2* sequence in MRI after thrombolysis</measure>
    <time_frame>1 day</time_frame>
    <description>The number of CMB is an important imaging marker reflecting microvascular injury.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">150</enrollment>
  <condition>Cerebral Infarction</condition>
  <arm_group>
    <arm_group_label>The experimental group</arm_group_label>
    <description>The application of raising serum brain granules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>The control group</arm_group_label>
    <description>No nourishing serum brain granules are used</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raise serum brain granules</intervention_name>
    <description>Should Yangseronao granules be used in patients undergoing intravenous thrombolysis for the diagnosis of acute ischemic stroke</description>
    <arm_group_label>The experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>No nourishing serum brain granules are used</intervention_name>
    <description>No nourishing serum brain granules are used</description>
    <arm_group_label>The control group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        A cohort of patients admitted to the Department of Emergency Neurology at Peking University&#xD;
        Third Hospital on January 1, 2017 and admitted on September 30, 2019, who were diagnosed&#xD;
        with acute ischemic stroke and underwent intravenous thrombolysis.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  A cohort of patients admitted to the Department of Emergency Neurology at Peking&#xD;
             University Third Hospital on January 1, 2017 and admitted on September 30, 2019, who&#xD;
             were diagnosed with acute ischemic stroke and underwent intravenous thrombolysis.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who underwent intravenous thrombolysis but were confirmed to be apoplexy&#xD;
&#xD;
          -  like by imaging and other clinical examinations; Incomplete craniocerebral MRI&#xD;
             examination;&#xD;
&#xD;
          -  Bridging endovascular therapy;&#xD;
&#xD;
          -  The previous application of Yangxuenao granules or other drugs with similar effects;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Peking Yniversity Third Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 27, 2021</study_first_submitted>
  <study_first_submitted_qc>July 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2021</study_first_posted>
  <last_update_submitted>July 2, 2021</last_update_submitted>
  <last_update_submitted_qc>July 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

